Skip to main navigation
Skip to search
Skip to main content
UTMB Health Research Expert Profiles Home
Help & FAQ
Home
Experts
Departments
Equipment
Projects/Grants
Publications
Activities
Press/Media
Honors
Impacts
Search by expertise, name or affiliation
Chemotherapy-induced immunomodulation in non-small-cell lung cancer: A rationale for combination chemoimmunotherapy
Hua Zheng
, Masha Zeltsman
, Marjorie G. Zauderer
, Takashi Eguchi
,
Raj G. Vaghjiani
, Prasad S. Adusumilli
Research output
:
Contribution to journal
›
Review article
›
peer-review
54
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Chemotherapy-induced immunomodulation in non-small-cell lung cancer: A rationale for combination chemoimmunotherapy'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Immunomodulation
100%
Non-small Cell Lung Cancer (NSCLC)
100%
Chemotherapy-induced
100%
Chemoimmunotherapy
100%
Chemotherapy
33%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
33%
Immunomodulatory Effect
33%
Checkpoint Blockade
33%
Objective Response Rate
33%
Survival Benefit
33%
Antitumor Efficacy
33%
Combinatorial Approach
33%
Tumor Immune Microenvironment
33%
Combinational Approaches
33%
Pharmacology, Toxicology and Pharmaceutical Science
Chemotherapy
100%
Immunomodulation
100%
Non Small Cell Lung Cancer
100%
Immunotherapy
75%
Neoplasm
25%
Preclinical Study
25%
Clinical Study
25%
Immunology and Microbiology
Immunotherapy
100%
Immunomodulation
100%